Home CMS Pharmaceutical's CMS-D001 Receives NMPA Approval for Ulcerative Colitis and Crohn's Disease Clinical Trials

CMS Pharmaceutical's CMS-D001 Receives NMPA Approval for Ulcerative Colitis and Crohn's Disease Clinical Trials

May 26, 2026 06:30 CST Updated 06:50
CMS

Professional Drug Developer